文献速递肺结节与肺癌

Medicare人群中低剂量CT肺癌筛查的使用与结局

Use and Outcomes of Low-Dose CT Scan Lung Cancer Screening in the Medicare Population.
PubMed 文献 · Chest · 2022-03-29

基于SEER-Medicare数据库分析2015—2019年低剂量CT筛查使用率及筛查后肺癌诊断特征。筛查使用率从2015年0.10/100人年升至2019年1.3/100人年,首次筛查后1年肺癌累积诊断率2.4%,筛查者以早期肺癌为主且3年肺癌特异性生存率更高。

要点

  • Medicare人群LDCT筛查使用率低但逐年上升,2019年达1.3/100人年。
  • 首次筛查后1年肺癌累积诊断率2.4%,筛查者Ⅰ期占52.3%。
  • 筛查者3年肺癌特异性生存率总体优于未筛查者,Ⅰ期达89.0%。

核心结论

  • Medicare人群中LDCT肺癌筛查使用率低但随时间增加,筛查后肺癌检出以早期为主且生存率较高,筛查结局良好。

研究设计与样本

  • 基于SEER-Medicare 5%样本构建LDCT使用队列(n=414,358),纳入2015—2019年65至77岁且有≥12个月非HMO Part A和B覆盖者。
  • 另建肺癌队列(n=48,891),纳入2015—2017年65至78岁诊断前一年有完整非HMO覆盖者,比较筛查与未筛查组的肺癌特征和生存。

主要发现

  • LDCT使用率从2015年0.10/100人年升至2019年1.3/100人年。
  • 首次筛查者中39.2%在18个月内接受后续筛查,首次筛查后1年肺癌累积诊断率2.4%。
  • 肺癌队列中1150例(2.4%)接受过筛查,筛查者Ⅰ、Ⅱ、Ⅲ、Ⅳ期分别占52.3%、11.0%、20.7%、16.0%。
  • 筛查者3年肺癌特异性生存率总体及除Ⅱ期外各分期均显著高于未筛查者,Ⅰ期筛查者3年肺癌特异性生存率为89.0%。

临床怎么用

  • 应关注Medicare人群LDCT筛查使用率低的问题,筛查后肺癌以早期为主且生存率高,支持在符合条件人群中推进筛查。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Relatively little is known about various aspects of low-dose CT (LDCT) scan lung cancer screening in US clinical practice, including characteristics of cases diagnosed after screening. We assessed this using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. RESEARCH QUESTION: What were the characteristics of patients with lung cancer, including stage and survival, whose disease was diagnosed after LDCT scan screenings? STUDY DESIGN AND METHODS: We created an LDCT scan use cohort consisting of everyone in the 5% SEER-Medicare sample with ≥ 12 months of non-health maintenance organization (HMO) Part A and B coverage while 65 to 77 years of age from 2015 through 2019. LDCT scan use and lung cancer diagnosis rates were assessed in this cohort. Additionally, we created a lung cancer cohort consisting of patients who received a diagnosis between 2015 and 2017 at 65 to 78 years of age with complete (non-HMO Part A and B) coverage the year before diagnosis. The cases cohort comprised those screened or unscreened based on undergoing screening during that period; lung cancer characteristics and survival were compared between these groups. RESULTS: In the LDCT scan use cohort (n = 414,358), use rates increased from 0.10 (per 100 person-years) in 2015 to 1.3 in 2019. Among those with first screenings, 39.2% underwent a subsequent screen within 18 months. The 1-year cumulative lung cancer diagnosis rate after initial screenings was 2.4%. Claims for prescreen counseling were infrequent (about 10%). Of 48,891 patients in the lung cancer cohort, 1,150 (2.4%) underwent screening. Among screened patients, 52.3%, 11.0%, 20.7%, and 16.0% received diagnoses of stages I, II, III, and IV disease, respectively. Lung cancer-specific survival through 3 years was significantly greater in screened versus unscreened patients overall and for all stages except stage II; 3-year lung cancer-specific survival was 89.0% in screened patients with stage I disease. INTERPRETATION: LDCT scan use was low but increased over time. The lung cancer yield was substantial; cases among those who underwent screening primarily were in the early stage with high survival rates. Although screening rates were unacceptably low, screening outcomes in those Medicare recipients undergoing screening were favorable.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Pinsky PF, Miller E. Use and Outcomes of Low-Dose CT Scan Lung Cancer Screening in the Medicare Population. Chest. 2022. PMID: 35364090. doi:10.1016/j.chest.2022.03.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。